SEARCH

SEARCH BY CITATION

References

  • Andrieux A., Salin P. A., Vernet M. et al. (2002) The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev. 16, 23502364.
  • Andrieux A., Salin P., Schweitzer A. et al. (2006) Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol. Psychiatry 60, 12241230.
  • Austin M. P., Mitchell P. and Goodwin G. M. (2001) Cognitive deficits in depression: possible implications for functional neuropathology. Br. J. Psychiatry 178, 200206.
  • Barten D. M., Fanara P., Andorfer C. et al. (2012) Hyperdynamic microtubules, cognitive deficits, and pathology are improved in Tau transgenic mice with low doses of microtubule-stabilizing agent BMS-241027. J. Neurosci. 32, 71377145.
  • Begou M., Brun P., Bertrand J. B., Job D., Schweitzer A., D'Amato T., Saoud M., Andrieux A. and Suaud-Chagny M. F. (2007) Post-pubertal emergence of alterations in locomotor activity in stop null mice. Synapse 61, 689697.
  • Benmansour S., Owens W. A., Cecchi M., Morilak D. A. and Frazer A. (2002) Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J. Neurosci. 22, 67666772.
  • Benson M. A., Sillitoe R. V. and Blake D. J. (2004) Schizophrenia genetics: dysbindin under the microscope. Trends Neurosci. 27, 516519.
  • Bianchi M., Shah A. J., Fone K. C., Atkins A. R., Dawson L. A., Heidbreder C. A., Hows M. E., Hagan J. J. and Marsden C. A. (2009) Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse 63, 359364.
  • Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L. and Bartesaghi R. (2010) Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 30, 87698779.
  • Blackwood D., Pickard B., Thomson P., Evans K., Porteous D. and Muir W. (2007) Are some genetic risk factors common to schizophrenia, bipolar disorder and depression ? Evidence from DISC1, GRIK4 and NRG1. Neurotox. Res. 11, 7383.
  • Blier P. and de Montigny C. (1994) Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15, 220226.
  • Bouvrais-Veret C., Weiss S., Andrieux A., Schweitzer A., McIntosh J. M., Job D., Giros B. and Martres M. P. (2007) Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology 52, 16911700.
  • Bouvrais-Veret C., Weiss S., Hanoun N., Andrieux A., Schweitzer A., Job D., Hamon M., Giros B. and Martres M. P. (2008) Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission. J. Neurochem. 104, 745756.
  • Brun P., Begou M., Andrieux A., Mouly-Badina L., Clerget M., Schweitzer A., Scarna H., Renaud B., Job D. and Suaud-Chagny M. F. (2005) Dopaminergic transmission in STOP null mice. J. Neurochem. 94, 6373.
  • Brunden K. R., Zhang B., Carroll J. et al. (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J. Neurosci. 30, 1386113866.
  • Chubb J. E., Bradshaw N. J., Soares D. C., Porteous D. J. and Millar J. K. (2008) The DISC locus in psychiatric illness. Mol. Psychiatry 13, 3664.
  • Delotterie D., Ruiz G., Brocard J., Schweitzer A., Roucard C., Roche Y., Suaud-Chagny M. F., Bressand K. and Andrieux A. (2010) Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice. Psychopharmacology 208, 131141.
  • Domschke K., Lawford B., Young R., Voisey J., Morris C. P., Roehrs T., Hohoff C., Birosova E., Arolt V. and Baune B. T. (2011) Dysbindin (DTNBP1)–a role in psychotic depression? J. Psychiatr. Res. 45, 588595.
  • Eaton W. W., Martins S. S., Nestadt G., Bienvenu O. J., Clarke D. and Alexandre P. (2008) The burden of mental disorders. Epidemiol. Rev. 30, 114.
  • Farley S., Dumas S., El Mestikawy S. and Giros B. (2012) Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 62, 503517.
  • Fournet V., Jany M., Fabre V. et al. (2010) The deletion of the microtubule-associated STOP protein affects the serotonergic mouse brain network. J. Neurochem. 115, 15791594.
  • Fournet V., Schweitzer A., Chevarin C., Deloulme J. C., Hamon M., Giros B., Andrieux A. and Martres M. P. (2012) The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances. J. Neurochem. 121, 99114.
  • Fradley R. L., O'Meara G. F., Newman R. J., Andrieux A., Job D. and Reynolds D. S. (2005) STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 163, 257264.
  • Frankle W. G., Lerma J. and Laruelle M. (2003) The synaptic hypothesis of schizophrenia. Neuron 39, 205216.
  • Gallassi R., Di Sarro R., Morreale A. and Amore M. (2006) Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J. Affect. Disord. 91, 243250.
  • Gardiner J., Overall R. and Marc J. (2011) The microtubule cytoskeleton acts as a key downstream effector of neurotransmitter signaling. Synapse 65, 249256.
  • Herman J. P., Figueiredo H., Mueller N. K., Ulrich-Lai Y., Ostrander M. M., Choi D. C. and Cullinan W. E. (2003) Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front. Neuroendocrinol. 24, 151180.
  • Hirano K., Seki T., Sakai N., Kato Y., Hashimoto H., Uchida S. and Yamada S. (2005) Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res. 1053, 154161.
  • Horsfield S. A., Rosse R. B., Tomasino V., Schwartz B. L., Mastropaolo J. and Deutsch S. I. (2002) Fluoxetine's effects on cognitive performance in patients with traumatic brain injury. Int. J. Psychiatry Med. 32, 337344.
  • Ishizuka K., Paek M., Kamiya A. and Sawa A. (2006) A review of Disrupted-In-Schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions. Biol. Psychiatry 59, 11891197.
  • Kajitani K., Thorne M., Samson M. and Robertson G. S. (2010) Nitric oxide synthase mediates the ability of darbepoetin alfa to improve the cognitive performance of STOP null mice. Neuropsychopharmacology 35, 17181728.
  • Kamiya A., Tomoda T., Chang J. et al. (2006) DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum. Mol. Genet. 15, 33133323.
  • Keefe R. S., Bilder R. M., Davis S. M. et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633647.
  • Kilpinen H., Ylisaukko-Oja T., Hennah W., Palo O. M., Varilo T., Vanhala R., Nieminen-von Wendt T., von Wendt L., Paunio T. and Peltonen L. (2008) Association of DISC1 with autism and Asperger syndrome. Mol. Psychiatry 13, 187196.
  • Kolman A. (2004) Epothilone D (Kosan/Roche). Curr. Opin. Investig. Drugs 5, 657667.
  • Lanfumey L., Mongeau R., Cohen-Salmon C. and Hamon M. (2008) Corticosteroid-serotonin interactions in the neurobiological mechanisms of stress-related disorders. Neurosci. Biobehav. Rev. 32, 11741184.
  • Levkovitz Y., Caftori R., Avital A. and Richter-Levin G. (2002) The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression. Brain Res. Bull. 58, 345350.
  • Li W. L., Cai H. H., Wang B., Chen L., Zhou Q. G., Luo C. X., Liu N., Ding X. S. and Zhu D. Y. (2009) Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J. Neurosci. Res. 87, 112122.
  • Lopez A. D., Mathers C. D., Ezzati M., Jamison D. T. and Murray C. J. (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367, 17471757.
  • Maier W. (2008) Common risk genes for affective and schizophrenic psychoses. Eur. Arch. Psychiatry Clin. Neurosci. 258(Suppl 2), 3740.
  • Mathers C. D. and Loncar D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442.
  • Matsuoka Y., Jouroukhin Y., Gray A. J. et al. (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146153.
  • McEwen B. S. (2003) Mood disorders and allostatic load. Biol. Psychiatry 54, 200207.
  • Merenlender-Wagner A., Pikman R., Giladi E., Andrieux A. and Gozes I. (2010) NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse–a microtubule-deficient model of schizophrenia. Peptides 31, 13681373.
  • Millan M. J., Dekeyne A., Papp M., La Rochelle C. D., MacSweeny C., Peglion J. L. and Brocco M. (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298, 581591.
  • Millar J. K., Wilson-Annan J. C., Anderson S. et al. (2000) Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum. Mol. Genet. 9, 14151423.
  • Mirnics K., Middleton F. A., Lewis D. A. and Levitt P. (2001) Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 24, 479486.
  • Morris J., Kandpal G., Ma L. and Austin C. (2003) DISC1(disrupted-in-schizophrenia 1) is a centrosome-assciated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss if interaction with mutation. Hum. Mol. Genet. 12, 15911608.
  • Mostert J. P., Koch M. W., Heerings M., Heersema D. J. and De Keyser J. (2008) Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci. Ther. 14, 153164.
  • Mowla A., Mosavinasab M. and Pani A. (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J. Clin. Psychopharmacol. 27, 6770.
  • Mutlu O., Ulak G., Laugeray A. and Belzung C. (2009) Effects of neuronal and inducible NOS inhibitor 1-[2-(trifluoromethyl) phenyl] imidazole (TRIM) in unpredictable chronic mild stress procedure in mice. Pharmacol. Biochem. Behav. 92, 8287.
  • Nettles J. H., Li H., Cornett B., Krahn J. M., Snyder J. P. and Downing K. H. (2004) The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 305, 866869.
  • Norton N., Williams H. J. and Owen M. J. (2006) An update on the genetics of schizophrenia. Curr. Opin. Psychiatry 19, 158164.
  • Owen M. J., Craddock N. and O'Donovan M. C. (2005) Schizophrenia: genes at last? Trends Genet. 21, 518525.
  • Pineyro G. and Blier P. (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol. Rev. 51, 533591.
  • Porsolt R. D., Bertin A., Blavet N., Deniel M. and Jalfre M. (1979) Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur. J. Pharmacol. 57, 201210.
  • Porter R. J., Gallagher P., Thompson J. M. and Young A. H. (2003) Neurocognitive impairment in drug-free patients with major depressive disorder. Br. J. Psychiatry 182, 214220.
  • Powell K. J., Hori S. E., Leslie R., Andrieux A., Schellinck H., Thorne M. and Robertson G. S. (2007) Cognitive impairments in the STOP null mouse model of schizophrenia. Behav. Neurosci. 121, 826835.
  • Schloesser R. J., Huang J., Klein P. S. and Manji H. K. (2008) Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33, 110133.
  • Seeman P., Schwarz J., Chen, J.-F. et al. (2006) Psychosis pathways converge via D2high dopamine receptors. Synapse 60, 319346.
  • Song L., Che W., Min-Wei W., Murakami Y. and Matsumoto K. (2006) Impairment of the spatial learning and memory induced by learned helplessness and chronic mild stress. Pharmacol. Biochem. Behav. 83, 186193.
  • Straub R. E., Jiang Y., MacLean C. J. et al. (2002) Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71, 337348.
  • Talbot K., Cho D. S., Ong W. Y., Benson M. A., Han L. Y., Kazi H. A., Kamins J., Hahn C. G., Blake D. J. and Arnold S. E. (2006) Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum. Mol. Genet. 15, 30413054.
  • Taya S., Shinoda T., Tsuboi D. et al. (2007) DISC1 regulates the transport of the NUDEL/LIS1/14-3-3e complex through kinesin-1. J. Neurosci. 27, 1526.
  • Weiland-Fiedler P., Erickson K., Waldeck T., Luckenbaugh D. A., Pike D., Bonne O., Charney D. S. and Neumeister A. (2004) Evidence for continuing neuropsychological impairments in depression. J. Affect. Disord. 82, 253258.
  • Yalcin I., Belzung C. and Surget A. (2008) Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav. Brain Res. 193, 140143.
  • Zhang B., Carroll J., Trojanowski J. Q. et al. (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J. Neurosci. 32, 36013611.